SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP
SPARC to receive 55% equity in Tiller Therapeutics
SPARC to receive 55% equity in Tiller Therapeutics
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Subscribe To Our Newsletter & Stay Updated